Mizuho analyst Salim Syed upgraded Atara Biotherapeutics to Outperform from Neutral with a price target of $18, down from $25. The analyst likes the underlying T-cell with which the company operates and notes the shares trade at a $40M market cap. Atara is closer to a potentially better 2025 with a tab-cel FDA action date of January 15, possibly triggering a $60M or $10 per share milestone receipt from Pierre Fabre, the analyst tells investors in a research note. Mizuho adds that Atara is one of the cell therapy stocks “that never really saw a tailwind from general investor interest in autoimmune.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Atara Biotherapeutics Announces CEO Transition and New Leadership Compensation
- Atara sees FY24 OpEx down roughly 35% year-over-year
- Atara Biotherapeutics reports Q2 EPS ($3.10), consensus ($1.56)
- Atara Biotherapeutics Inc (ATRA) Q2 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today